| Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised … AMM Eggermont, CU Blank, M Mandalà, GV Long, VG Atkinson, S Dalle, ... The lancet oncology 22 (5), 643-654, 2021 | 290 | 2021 |
| Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial GV Long, V Atkinson, JS Cebon, MB Jameson, BM Fitzharris, CM McNeil, ... The Lancet Oncology 18 (9), 1202-1210, 2017 | 276 | 2017 |
| Effects of 5, 6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging SM Galbraith, GJS Rustin, MA Lodge, NJ Taylor, JJ Stirling, M Jameson, ... Journal of clinical oncology 20 (18), 3826-3840, 2002 | 169 | 2002 |
| Induction of endothelial cell apoptosis by the antivascular agent 5, 6-dimethylxanthenone-4-acetic acid LM Ching, Z Cao, C Kieda, S Zwain, MB Jameson, BC Baguley British journal of cancer 86 (12), 1937-1942, 2002 | 154 | 2002 |
| Successful triage of patients referred to a skin lesion clinic using teledermoscopy (IMAGE IT trial) E Tan, A Yung, M Jameson, A Oakley, M Rademaker British Journal of Dermatology 162 (4), 803-811, 2010 | 150 | 2010 |
| Clinical aspects of a phase I trial of 5, 6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent MB Jameson, PI Thompson, BC Baguley, BD Evans, VJ Harvey, DJ Porter, ... British journal of cancer 88 (12), 1844-1850, 2003 | 149 | 2003 |
| Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer MJ McKeage, J Von Pawel, M Reck, MB Jameson, MA Rosenthal, ... British Journal of Cancer 99 (12), 2006-2012, 2008 | 141 | 2008 |
| Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors J Desai, S Deva, JS Lee, CC Lin, CJ Yen, Y Chao, B Keam, M Jameson, ... Journal for immunotherapy of cancer 8 (1), 2020 | 117 | 2020 |
| Phase II study of ASA404 (vadimezan, 5, 6-dimethylxanthenone-4-acetic acid/DMXAA) 1800 mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small … MJ McKeage, M Reck, MB Jameson, MA Rosenthal, D Gibbs, ... Lung cancer 65 (2), 192-197, 2009 | 113 | 2009 |
| 5, 6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent MJ McKeage, P Fong, M Jeffery, BC Baguley, P Kestell, M Ravic, ... Clinical cancer research 12 (6), 1776-1784, 2006 | 111 | 2006 |
| Review of high‐dose intravenous vitamin C as an anticancer agent MK Wilson, BC Baguley, C Wall, MB Jameson, MP Findlay Asia‐Pacific Journal of Clinical Oncology 10 (1), 22-37, 2014 | 108 | 2014 |
| A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors MB Jameson, D Rischin, M Pegram, J Gutheil, AV Patterson, WA Denny, ... Cancer chemotherapy and pharmacology 65, 791-801, 2010 | 105 | 2010 |
| A phase 1 study of AS1409, a novel antibody-cytokine fusion protein, in patients with malignant melanoma or renal cell carcinoma SM Rudman, MB Jameson, MJ McKeage, P Savage, DI Jodrell, M Harries, ... Clinical Cancer Research 17 (7), 1998-2005, 2011 | 96 | 2011 |
| Phase I, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors J Desai, H Gan, C Barrow, M Jameson, V Atkinson, A Haydon, M Millward, ... Journal of Clinical Oncology 38 (19), 2140, 2020 | 84 | 2020 |
| Optimising selenium for modulation of cancer treatments SO Evans, PF Khairuddin, MB Jameson Anticancer research 37 (12), 6497-6509, 2017 | 79 | 2017 |
| A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients MJ McKeage, Y Gu, WR Wilson, A Hill, K Amies, TJ Melink, MB Jameson BMC cancer 11, 1-12, 2011 | 71 | 2011 |
| PR-104 a bioreductive pre-prodrug combined with gemcitabine or docetaxel in a phase Ib study of patients with advanced solid tumours MJ McKeage, MB Jameson, RK Ramanathan, J Rajendran, Y Gu, ... BMC cancer 12, 1-10, 2012 | 67 | 2012 |
| Impact of geriatric assessment on the management of older adults with head and neck cancer: a pilot study M Neve, MB Jameson, S Govender, C Hartopeanu Journal of geriatric oncology 7 (6), 457-462, 2016 | 62 | 2016 |
| Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: Results of the KEYNOTE-029 expansion cohort. GV Long, V Atkinson, JS Cebon, MB Jameson, BM Fitzharris, CM McNeil, ... Journal of Clinical Oncology 34 (15_suppl), 9506-9506, 2016 | 62 | 2016 |
| Phase IB trial of the anti-cancer stem cell DLL4-binding agent demcizumab with pemetrexed and carboplatin as first-line treatment of metastatic non-squamous NSCLC MJ McKeage, D Kotasek, B Markman, M Hidalgo, MJ Millward, ... Targeted Oncology 13, 89-98, 2018 | 58 | 2018 |
Mark McKeageProfessorVerified email at auckland.ac.nz
